JP2013515013A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515013A5
JP2013515013A5 JP2012545019A JP2012545019A JP2013515013A5 JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5 JP 2012545019 A JP2012545019 A JP 2012545019A JP 2012545019 A JP2012545019 A JP 2012545019A JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
antibody fragment
fragment according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012545019A
Other languages
English (en)
Japanese (ja)
Other versions
JP5992831B2 (ja
JP2013515013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2010/001741 external-priority patent/WO2011075789A1/en
Publication of JP2013515013A publication Critical patent/JP2013515013A/ja
Publication of JP2013515013A5 publication Critical patent/JP2013515013A5/ja
Application granted granted Critical
Publication of JP5992831B2 publication Critical patent/JP5992831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012545019A 2009-12-24 2010-12-23 非機能性オリゴマーp2x7受容体に対する抗体 Active JP5992831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009906286A AU2009906286A0 (en) 2009-12-24 Anti P2X7 receptor antibodies and fragments thereof
AU2009906286 2009-12-24
PCT/AU2010/001741 WO2011075789A1 (en) 2009-12-24 2010-12-23 Antibodies to non-functional oligomeric p2x7 receptors

Publications (3)

Publication Number Publication Date
JP2013515013A JP2013515013A (ja) 2013-05-02
JP2013515013A5 true JP2013515013A5 (cg-RX-API-DMAC7.html) 2014-02-13
JP5992831B2 JP5992831B2 (ja) 2016-09-14

Family

ID=44194835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012545019A Active JP5992831B2 (ja) 2009-12-24 2010-12-23 非機能性オリゴマーp2x7受容体に対する抗体

Country Status (9)

Country Link
US (2) US8835609B2 (cg-RX-API-DMAC7.html)
EP (2) EP2516470B1 (cg-RX-API-DMAC7.html)
JP (1) JP5992831B2 (cg-RX-API-DMAC7.html)
CN (1) CN102762595B (cg-RX-API-DMAC7.html)
AU (1) AU2010336032C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012015561B1 (cg-RX-API-DMAC7.html)
CA (1) CA2784345C (cg-RX-API-DMAC7.html)
ES (2) ES2732021T3 (cg-RX-API-DMAC7.html)
WO (1) WO2011075789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158262A (en) 2001-01-17 2016-09-30 Biosceptre (Aust) Pty Ltd Diagnosis and treatments of cancers and other conditions
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
BR112013033974A2 (pt) 2011-07-01 2017-02-14 Biosceptre Int Ltd terapia de combinação
JPWO2014003137A1 (ja) * 2012-06-27 2016-06-02 旭化成メディカル株式会社 高アフィニティー抗体、及びその製造方法
AU2016240410B2 (en) * 2015-04-02 2021-09-16 Biosceptre (Aust) Pty Ltd Pain treatment
CN108350462B (zh) 2015-09-11 2022-05-27 生物权威(英国)有限公司 嵌合抗原受体及其用途
WO2018071959A1 (en) 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
EP3755327A4 (en) * 2018-02-23 2021-11-24 REMD Biotherapeutics, Inc. CALCITONIN GENE-RELATED PEPTIDE ANTAGONIST ANTIBODIES (CGRP)
WO2019229296A1 (en) 2018-05-29 2019-12-05 Teknologian Tutkimuskeskus Vtt Oy Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
US20220251187A1 (en) * 2019-07-26 2022-08-11 Biosceptre (Aust) Pty Ltd P2x7 receptor targeted therapy
CA3211323A1 (en) * 2021-03-11 2022-09-15 Patrick Schlegel Novel cell therapy system
US20240368282A1 (en) * 2021-09-01 2024-11-07 Biosceptre (Aust) Pty Ltd Methods and compositions for stimulating immune activity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
WO1995033048A2 (en) 1994-05-27 1995-12-07 Glaxo Group Limited P2x receptors (purinoceptor family)
JPH11510393A (ja) 1995-08-09 1999-09-14 インスティチュート ナショナル ドゥ ラ セント エト ドゥ ラ リサーチェ メディカル 白血病マーカーとしておよび乳癌の予後において有用な単離された核酸分子
WO1997041222A1 (en) 1996-04-30 1997-11-06 Smithkline Beecham P.L.C. HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
JP4855577B2 (ja) 1998-06-01 2012-01-18 アジェンシス,インコーポレイテッド ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
WO2000050458A1 (en) 1999-02-26 2000-08-31 Smithkline Beecham Corporation Cloning of a p2y-like 7tm receptor (axor17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
MY158262A (en) 2001-01-17 2016-09-30 Biosceptre (Aust) Pty Ltd Diagnosis and treatments of cancers and other conditions
CA2459348C (en) * 2001-09-03 2013-06-18 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
MXPA05011008A (es) 2003-04-17 2006-03-08 Affectis Pharmaceuticals Ag Medios y metodos para diagnosticar y tratar trastornos afectivos.
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100036101A1 (en) 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
BR112013033974A2 (pt) 2011-07-01 2017-02-14 Biosceptre Int Ltd terapia de combinação

Similar Documents

Publication Publication Date Title
JP2013515013A5 (cg-RX-API-DMAC7.html)
JP2014511179A5 (cg-RX-API-DMAC7.html)
JP2013502204A5 (cg-RX-API-DMAC7.html)
JP2014512809A5 (cg-RX-API-DMAC7.html)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2009532336A5 (cg-RX-API-DMAC7.html)
JP2017052784A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
RU2017126476A (ru) Новые модуляторы и способы их применения
JP2020522261A5 (cg-RX-API-DMAC7.html)
JP2014526898A5 (cg-RX-API-DMAC7.html)
JP2009225799A5 (cg-RX-API-DMAC7.html)
JP2016516400A5 (cg-RX-API-DMAC7.html)
JP2013198490A5 (cg-RX-API-DMAC7.html)
JP2013538057A5 (cg-RX-API-DMAC7.html)
JP2018504105A5 (cg-RX-API-DMAC7.html)
NZ598670A (en) Antibodies against glucagon receptor and their use
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
JP2018512379A5 (cg-RX-API-DMAC7.html)
HRP20211444T1 (hr) Anti-dll3 antitijelo
JP2011207882A5 (cg-RX-API-DMAC7.html)
JP2017500028A5 (cg-RX-API-DMAC7.html)
JP2017519759A5 (cg-RX-API-DMAC7.html)
JP2010042025A5 (cg-RX-API-DMAC7.html)
JP2010516229A5 (cg-RX-API-DMAC7.html)